SOURCE: SciClone Pharmaceuticals, Inc.

May 01, 2007 06:30 ET

SciClone Pharmaceuticals to Report First Quarter Results on May 8, 2007

SciClone to Present at Burrill's China Life Sciences Partnering Meeting on May 5, 2007

SAN MATEO, CA -- (MARKET WIRE) -- May 1, 2007 --SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report first quarter 2007 results and host a conference call on Tuesday, May 8, 2007.

The conference call will contain forward-looking statements. Financial and statistical information to be discussed will be posted on the Investor Relations section of SciClone's website at prior to the commencement of the conference call.

DATE:           Tuesday, May, 8, 2007
TIME:           11:30 a.m. ET (8:30 a.m. PT)
WEBCAST:        Live call and replay accessible at
LIVE CALL:      800-817-2743 (U.S./Canada)
                913-981-4915 (International)
REPLAY:         888-203-1112 (U.S./Canada)
                719-457-0820 (International)
                7435759 (Replay passcode)
                (Replay available from 2:30 p.m. ET on May 8, 2007
                through 11:59 p.m. ET on Tuesday, May 22, 2007)
Additionally, Friedhelm Blobel, Ph.D., President and Chief Executive Officer of SciClone Pharmaceuticals will give a presentation at the China Life Sciences Partnering Meeting hosted by Burrill & Company on May 5, 2007 at 2:40 p.m. ET in Boston, Massachusetts. The presentation will include an overview of SciClone's Chinese operations and give an outlook for the Chinese pharmaceutical market.

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage in the rapidly growing Chinese market by in-licensing or acquiring the marketing rights to other products, such as DC Bead™ for the treatment of liver cancer. For the U.S. market, SciClone's clinical-stage drug development candidates are SCV-07 for the treatment of viral infectious diseases and RP101 for the treatment of pancreatic cancer. For more information about SciClone, visit

The information in Dr. Blobel's presentation may contain forward-looking statements including our expectations and beliefs regarding future sales, strategic objectives and financial results for 2007, and progress and results of our clinical trials. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended" and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, goals, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, including changes in demand for ZADAXIN or DC Bead, the progress or failure of clinical trials, our actual experience in executing on our objectives, the performance of our partners, maintenance of the sufficiency and eligibility of the enrolled patient population, unanticipated delays or additional expenses incurred during our clinical trials, our future cash requirements, delays in analyzing and synthesizing data obtained from clinical trials, future actions of our strategic partners, unexpected delays in preparation for enrollment, future actions by the U.S. Food and Drug Administration or equivalent regulatory authorities in Europe and, with respect to DC Bead, in China, and the fact that experimental data and clinical results derived from studies with a limited group of patients may not be predictive of the results of larger studies, as well as other risks and uncertainties described in SciClone's filings with the Securities and Exchange Commission.

Contact Information

  • Corporate Contact:
    Richard Waldron
    Executive Vice President and Chief Financial Officer
    SciClone Pharmaceuticals, Inc.